Stifel Maintains Buy on X4 Pharmaceuticals, Lowers Price Target to $4
Stifel Maintains Buy on X4 Pharmaceuticals, Lowers Price Target to $4
Stifel維持對x4製藥的買入評級，將目標價格下調至4美元。
Stifel analyst Stephen Willey maintains X4 Pharmaceuticals (NASDAQ:XFOR) with a Buy and lowers the price target from $5 to $4.
Stifel分析師Stephen Willey認爲x4製藥（納斯達克：XFOR）值得買入，並將目標股價從5美元下調至4美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。